| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/29/2004 | US20040081650 Inflammatory mediator antagonists |
| 04/29/2004 | US20040081645 Glycogen storage disease type II treatment comprising human acid glucosidase, mannitol and sucrose in aqueous solution |
| 04/29/2004 | US20040081635 Antiinflammatory agents; anticancer agents; bactericides; fungicides; autoimmune diseases; mixture of interferons with carriers |
| 04/29/2004 | US20040081631 Cosmetic composition for skin whitening comprising senkyunolide a as active ingredient |
| 04/29/2004 | US20040081624 Mixture containing high volatility carrier; vaporization; mixing with air |
| 04/29/2004 | CA2502211A1 Azo compounds for type i phototherapy |
| 04/29/2004 | CA2501556A1 Remedy for hormone-dependent cancer |
| 04/29/2004 | CA2501093A1 Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain |
| 04/29/2004 | CA2500417A1 Neurotrophic factor production promoter |
| 04/29/2004 | CA2496633A1 Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
| 04/28/2004 | EP1413583A2 Compounds that inhibit T cell proliferation and methods using the same |
| 04/28/2004 | EP1413581A1 Rapamycin derivatives |
| 04/28/2004 | EP1413580A1 Furanone derivatives as inhibitors of Cathepsin S |
| 04/28/2004 | EP1413578A1 Novel crystal of arylethenesulfonamide derivative and process for producing the same |
| 04/28/2004 | EP1413576A2 Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| 04/28/2004 | EP1413332A1 Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
| 04/28/2004 | EP1413315A1 Sustained-release medicines |
| 04/28/2004 | EP1413314A1 Medicinal compositions |
| 04/28/2004 | EP1413313A1 DIAGNOSIS AND TREATMENT OF INSULIN−DEPENDENT DIABETES MELLITUS AND INSULITIS |
| 04/28/2004 | EP1413310A1 Sustained-release compositions for injection and process for producing the same |
| 04/28/2004 | EP1413307A1 Therapeutically active levorotatory and dextrorotatory 1-(4-chlorophenyl)phenylmethyl piperazines |
| 04/28/2004 | EP1413304A1 Use of combination of carnitine and lipoic acid for restoring mitochondrial function |
| 04/28/2004 | EP1413303A1 Swine growth promoters and method of promoting swine growth |
| 04/28/2004 | EP1413201A2 Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals |
| 04/28/2004 | EP1413116A1 Access control system |
| 04/28/2004 | EP1412523A2 Methods of profiling gene expression, protein or metabolite levels |
| 04/28/2004 | EP1412499A2 Cytokine polypeptides |
| 04/28/2004 | EP1412492A2 Regulator of calcineurin |
| 04/28/2004 | EP1412484A1 Use of lysyl oxidase inhibitors for cell culture and tissue engineering |
| 04/28/2004 | EP1412477A2 GPCs AS MODIFIERS OF THE IRRTK AND P21 PATHWAYS AND METHODS OF USE |
| 04/28/2004 | EP1412377A1 Production of high molecular mass lectins |
| 04/28/2004 | EP1412368A2 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain |
| 04/28/2004 | EP1412364A1 Platelet adp receptor inhibitors |
| 04/28/2004 | EP1412363A1 Gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1412362A1 Chemical compounds |
| 04/28/2004 | EP1412361A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 04/28/2004 | EP1412357A1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 04/28/2004 | EP1412354A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS |
| 04/28/2004 | EP1412353A1 Imidazopyridinones as p38 map kinase inhibitors |
| 04/28/2004 | EP1412352A1 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands |
| 04/28/2004 | EP1412349A2 Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
| 04/28/2004 | EP1412343A1 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 04/28/2004 | EP1412338A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1412330A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/28/2004 | EP1412327A2 Inhibitors of protein kinase for the treatment of disease |
| 04/28/2004 | EP1412325A1 Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| 04/28/2004 | EP1412324A2 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 04/28/2004 | EP1412317A1 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities |
| 04/28/2004 | EP1412029A2 Combinations comprising epothilones and pharmaceutical uses thereof |
| 04/28/2004 | EP1412028A1 Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| 04/28/2004 | EP1411993A2 Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| 04/28/2004 | EP1411989A2 Methods for improving cell line activity in immunoisolation devices |
| 04/28/2004 | EP1411984A2 Combination medicament for treatment of neoplastic diseases which contains cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
| 04/28/2004 | EP1411982A1 Modulators of p-selectin glycoprotein ligand 1 |
| 04/28/2004 | EP1411970A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 04/28/2004 | EP1411968A2 Glp-1 exendin-4 peptide analogs and uses thereof |
| 04/28/2004 | EP1411967A2 Blocking peptide for inflammatory cell secretion |
| 04/28/2004 | EP1411952A1 Use of at least one glycoinhibitor substance |
| 04/28/2004 | EP1411947A2 Salts of substituted 1, 2, 3, 4-tetrahydroisoquinoline-2-carboxylic acid derivatives |
| 04/28/2004 | EP1411946A1 Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
| 04/28/2004 | EP1411945A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1411944A1 Sulfonamide derivatives as gamma secretase inhibitors |
| 04/28/2004 | EP1411942A1 Substituted anilinic piperidines as mch selective antagonists |
| 04/28/2004 | EP1411940A1 Bridged piperidine derivatives as melanocortin receptor agonists |
| 04/28/2004 | EP1411935A1 Use of 4- (4-thiazolyl)phenoxl] alkoxy-benzamidine derivatives for treatment of osteoporosis |
| 04/28/2004 | EP1411933A1 Alpha-ketoamide derivatives as cathepsin k inhibitors |
| 04/28/2004 | EP1411932A1 Substituted oxazolidinones for combinational therapy |
| 04/28/2004 | EP1411929A2 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 04/28/2004 | EP1411928A1 Viral polymerase inhibitors |
| 04/28/2004 | EP1411925A1 5-arylsulfonyl indoles having 5-ht6 receptor affinity |
| 04/28/2004 | EP1411923A1 Pharmaceutical compositions of amlodipine and atorvastatin |
| 04/28/2004 | EP1411918A2 Methods to mobilize progenitor/stem cells |
| 04/28/2004 | EP1411914A2 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma |
| 04/28/2004 | EP1411907A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma |
| 04/28/2004 | EP1411900A2 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs |
| 04/28/2004 | EP1411898A1 Pharmaceutical composition comprising lipids with a polar and a nonpolar moiety |
| 04/28/2004 | EP1411890A1 Cosmetic and/or pharmaceutical preparations containing plant extracts |
| 04/28/2004 | EP1411881A2 5HT sb 2C /sb RECEPTOR MODULATORS |
| 04/28/2004 | EP1307213B1 Chlorella preparations exhibiting immunomodulating properties |
| 04/28/2004 | EP1289986B1 1,4-diazabicyclo 3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof |
| 04/28/2004 | EP1286684B1 use of cxcr4 antagonists for treating autoimmune diseases and cancer |
| 04/28/2004 | EP1263718B1 Novel use of phenylheteroalkylamine derivatives |
| 04/28/2004 | EP1263715B1 Novel phenylheteroalkylamine derivatives |
| 04/28/2004 | EP1263714B1 Novel phenylheteroalkylamine derivatives |
| 04/28/2004 | EP1255559B1 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/28/2004 | EP1244642B1 Substituted oxazoles and thiazoles derivatives as hppar alpha activators |
| 04/28/2004 | EP1227098B1 Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents |
| 04/28/2004 | EP1162981B1 Dexrazoxane for the treatment of accidental extravasation of anthracyclines |
| 04/28/2004 | EP1083171B1 Pyrazoline derivatives, their preparation and application as medicaments |
| 04/28/2004 | EP1061946B1 Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
| 04/28/2004 | EP1058555B1 Costimulatory blockade and mixed chimerism in allotransplantation |
| 04/28/2004 | EP1039892B1 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis |
| 04/28/2004 | EP0937045B1 N-aryl substituted tetrahydroquinolines ligands for retinoid receptors having agonist, antagonist or inverse agonist type activity |
| 04/28/2004 | EP0915842B1 Nitrate esters and their use for neurological conditions |
| 04/28/2004 | EP0910645B1 A KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF I-kappa-B-alpha |
| 04/28/2004 | EP0730469B1 Modified truncated complement system regulators |
| 04/28/2004 | EP0719253B1 3-amino-5-carboxy-substituted piperidines and 3-amino-4-carboxy-substituted pyrrolidines as tachykinin antagonists |
| 04/28/2004 | EP0698095B1 Bmp-10 compositions |
| 04/28/2004 | EP0585366B1 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
| 04/28/2004 | EP0584068B2 Method and composition for ameliorating the adverse effects of aging |